标题
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
作者
关键词
-
出版物
NATURE
Volume 543, Issue 7647, Pages 733-737
出版商
Springer Nature
发表日期
2017-03-22
DOI
10.1038/nature21702
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
- (2015) L Kalmanti et al. LEUKEMIA
- Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
- (2015) Hyo-eun C Bhang et al. NATURE MEDICINE
- Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
- (2014) S. Branford et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Evolutionary dynamics of cancer in response to targeted combination therapy
- (2013) Ivana Bozic et al. eLife
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy
- (2011) H. M. Kantarjian et al. CLINICAL CANCER RESEARCH
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia
- (2010) Aref Al-Kali et al. CANCER
- Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay
- (2010) Wolfgang Jahnke et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
- (2010) Jianming Zhang et al. NATURE
- Extended kinase profile and properties of the protein kinase inhibitor nilotinib
- (2009) Paul W. Manley et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
- (2009) C Tanaka et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started